SUNITINIB

SynDRA canonical compound SYN0000677 — structure-anchored drug synonym record

Clinical phase	Launched
Approval status	Approved · Rx/OTC
Primary target(s)	CSF1R \| FGFR1 \| FLT1 \| FLT3 \| FLT4 \| KDR \| KIT \| PDGFRA \| PDGFRB \| RET
Mechanism of action	FLT3 inhibitor \| KIT inhibitor \| PDGFR tyrosine kinase receptor inhibitor \| RET tyrosine kinase inhibitor \| VEGFR inhibitor
Indication	gastrointestinal stromal tumors (GIST) \| neuroendocrine tumors of pancreatic origin (PNET) \| renal cell carcinoma (RCC)
Disease area	oncology

All known targets

sunitinib malate
sutent
SU-011248
SU-010398
PHA-290940AD
NSC-736511
NSC-750690
SU-11248
SU011248
Sunitinib accord
Sunitanib
Sunitinibum
Sutent
PDGF TK antagonist
SU11248
KS-5022
SU-11248J
SU-12662
Su-011248
Sunitinib (INN)
Sunitinib (free base)
Sutent (TN)
N-(2-diethylaminoethyl)-5-[(Z)-(5-fluoro-2-oxo-1H-indol-3-ylidene)methyl]-2,4-dimethyl-1H-pyrrole-3-carboxamide
N-[2-(diethylamino)ethyl]-5-[(Z)-(5-fluoro-2-oxo-1,2-dihydro-3H-indol-3-ylidene)methyl]-2,4-dimethyl-1H-pyrrole-3-carboxamide
5-(5-FLUORO-2-OXO-1,2-DIHYDRO-INDOL-3-YLIDENEMETHYL)-2,4-DIMETHYL-1H-PYRROLE-3-CARBOXYLIC ACID (2-DIETHYLAMINO-ETHYL)-AMIDE
Sunitinib (Pan-TK inhibitor)
SU 11248
Sunitinib Base
sunitinibum
(Z)-N-(2-(Diethylamino)ethyl)-5-((5-fluoro-2-oxoindolin-3-ylidene)methyl)-2,4-dimethyl-1H-pyrrole-3-carboxamide
Sunitinib [INN]
N-(2-(Diethylamino)ethyl)-5-((5-fluoro-2-oxoindolin-3-ylidene)methyl)-2,4-dimethyl-1H-pyrrole-3-carboxamide
N-[2-(diethylamino)ethyl]-5-{[(3Z)-5-fluoro-2-oxo-2,3-dihydro-1H-indol-3-ylidene]methyl}-2,4-dimethyl-1H-pyrrole-3-carboxamide
CHEMBL535
NSC 750690
CHEBI:38940
NSC750690
Sunitinib, Free base